Raj Wadwa
Concepts (320)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetes Mellitus, Type 1 | 121 | 2024 | 3248 | 8.850 |
Why?
| Insulin Infusion Systems | 39 | 2023 | 297 | 4.470 |
Why?
| Blood Glucose | 63 | 2024 | 1821 | 3.840 |
Why?
| Insulin | 44 | 2023 | 2079 | 3.260 |
Why?
| Hypoglycemic Agents | 43 | 2023 | 1008 | 3.150 |
Why?
| Blood Glucose Self-Monitoring | 38 | 2024 | 498 | 2.880 |
Why?
| Hypoglycemia | 25 | 2023 | 386 | 2.320 |
Why?
| Pancreas, Artificial | 16 | 2021 | 68 | 2.010 |
Why?
| Diabetic Angiopathies | 16 | 2019 | 244 | 1.700 |
Why?
| Vascular Stiffness | 14 | 2019 | 408 | 1.640 |
Why?
| Cardiovascular Diseases | 25 | 2019 | 1729 | 1.630 |
Why?
| Adolescent | 95 | 2024 | 17829 | 1.410 |
Why?
| Child | 73 | 2024 | 18366 | 1.160 |
Why?
| Telemedicine | 3 | 2022 | 665 | 1.000 |
Why?
| Diabetes Mellitus, Type 2 | 11 | 2020 | 2096 | 0.960 |
Why?
| Albuminuria | 4 | 2019 | 164 | 0.950 |
Why?
| Young Adult | 52 | 2023 | 10478 | 0.900 |
Why?
| Hyperglycemia | 11 | 2022 | 292 | 0.880 |
Why?
| Humans | 135 | 2024 | 114937 | 0.800 |
Why?
| Dyslipidemias | 4 | 2019 | 154 | 0.780 |
Why?
| Male | 92 | 2024 | 55663 | 0.750 |
Why?
| Female | 94 | 2024 | 59581 | 0.740 |
Why?
| Biosensing Techniques | 2 | 2020 | 99 | 0.720 |
Why?
| Uromodulin | 1 | 2019 | 21 | 0.660 |
Why?
| Glycopeptides | 1 | 2019 | 43 | 0.650 |
Why?
| Carotid Intima-Media Thickness | 3 | 2018 | 65 | 0.590 |
Why?
| Insulin Lispro | 4 | 2022 | 35 | 0.580 |
Why?
| Biomarkers | 10 | 2020 | 3418 | 0.580 |
Why?
| Child, Preschool | 19 | 2023 | 9086 | 0.560 |
Why?
| Ketones | 2 | 2016 | 45 | 0.550 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2014 | 372 | 0.540 |
Why?
| Adult | 53 | 2024 | 30608 | 0.520 |
Why?
| Autonomic Nervous System | 3 | 2013 | 70 | 0.510 |
Why?
| Cholesterol | 6 | 2020 | 368 | 0.500 |
Why?
| Diabetic Nephropathies | 5 | 2019 | 234 | 0.490 |
Why?
| Remote Consultation | 1 | 2015 | 42 | 0.480 |
Why?
| Patient Compliance | 2 | 2015 | 526 | 0.470 |
Why?
| Monitoring, Ambulatory | 4 | 2020 | 81 | 0.430 |
Why?
| Calcinosis | 4 | 2014 | 242 | 0.430 |
Why?
| Patient Education as Topic | 4 | 2019 | 678 | 0.420 |
Why?
| Cystatin C | 2 | 2015 | 62 | 0.420 |
Why?
| Diagnostic Techniques, Cardiovascular | 2 | 2014 | 11 | 0.410 |
Why?
| Case-Control Studies | 13 | 2020 | 3008 | 0.410 |
Why?
| Risk Factors | 27 | 2019 | 8637 | 0.400 |
Why?
| Glucagon | 3 | 2016 | 93 | 0.390 |
Why?
| Triglycerides | 9 | 2022 | 470 | 0.390 |
Why?
| Reproducibility of Results | 9 | 2024 | 2770 | 0.390 |
Why?
| Algorithms | 11 | 2022 | 1474 | 0.380 |
Why?
| Diabetic Ketoacidosis | 5 | 2022 | 160 | 0.380 |
Why?
| Arteries | 2 | 2010 | 247 | 0.370 |
Why?
| Insulin Aspart | 3 | 2022 | 26 | 0.370 |
Why?
| Quality of Life | 5 | 2022 | 2359 | 0.370 |
Why?
| Self-Management | 2 | 2023 | 126 | 0.360 |
Why?
| Graves Disease | 1 | 2010 | 32 | 0.350 |
Why?
| Adipose Tissue | 3 | 2022 | 539 | 0.350 |
Why?
| Middle Aged | 32 | 2023 | 26806 | 0.330 |
Why?
| Friedreich Ataxia | 1 | 2010 | 64 | 0.330 |
Why?
| Glomerular Filtration Rate | 4 | 2019 | 604 | 0.330 |
Why?
| Cholesterol, LDL | 4 | 2014 | 307 | 0.320 |
Why?
| Psychometrics | 3 | 2021 | 608 | 0.310 |
Why?
| Diabetes Complications | 2 | 2007 | 211 | 0.310 |
Why?
| Vascular Diseases | 2 | 2013 | 230 | 0.300 |
Why?
| Hyperlipidemias | 2 | 2007 | 122 | 0.300 |
Why?
| Pulse Wave Analysis | 10 | 2019 | 208 | 0.300 |
Why?
| Skiing | 2 | 2019 | 41 | 0.300 |
Why?
| Practice Guidelines as Topic | 1 | 2015 | 1400 | 0.300 |
Why?
| Insulin Resistance | 6 | 2019 | 1072 | 0.270 |
Why?
| Calibration | 4 | 2019 | 125 | 0.260 |
Why?
| Coronary Artery Disease | 3 | 2007 | 607 | 0.260 |
Why?
| Receptors, Interleukin-2 | 1 | 2005 | 64 | 0.260 |
Why?
| Exercise | 5 | 2019 | 1643 | 0.260 |
Why?
| Blood Pressure | 7 | 2014 | 1537 | 0.250 |
Why?
| Self Report | 2 | 2020 | 696 | 0.250 |
Why?
| Apolipoproteins B | 1 | 2014 | 41 | 0.240 |
Why?
| Heart Rate | 5 | 2019 | 705 | 0.230 |
Why?
| Body Mass Index | 10 | 2020 | 1961 | 0.230 |
Why?
| Infusion Pumps, Implantable | 2 | 2020 | 20 | 0.220 |
Why?
| Uric Acid | 2 | 2015 | 148 | 0.220 |
Why?
| Pilot Projects | 2 | 2020 | 1372 | 0.220 |
Why?
| Adiponectin | 4 | 2012 | 213 | 0.220 |
Why?
| Kidney | 3 | 2022 | 1184 | 0.210 |
Why?
| Diabetic Neuropathies | 3 | 2019 | 79 | 0.210 |
Why?
| Hypertension | 4 | 2019 | 1059 | 0.210 |
Why?
| Blood Vessels | 2 | 2018 | 180 | 0.210 |
Why?
| Lipids | 3 | 2014 | 582 | 0.200 |
Why?
| Cholesterol, HDL | 4 | 2014 | 184 | 0.200 |
Why?
| Insulin, Regular, Human | 4 | 2023 | 33 | 0.200 |
Why?
| Adiposity | 2 | 2018 | 457 | 0.200 |
Why?
| Age Factors | 9 | 2016 | 2891 | 0.200 |
Why?
| Computer Systems | 2 | 2018 | 45 | 0.190 |
Why?
| Cohort Studies | 11 | 2017 | 4903 | 0.190 |
Why?
| Technology | 1 | 2022 | 79 | 0.190 |
Why?
| Guideline Adherence | 2 | 2015 | 490 | 0.190 |
Why?
| Cross-Over Studies | 6 | 2019 | 441 | 0.180 |
Why?
| Glycosides | 1 | 2021 | 33 | 0.180 |
Why?
| Adolescent Behavior | 2 | 2017 | 488 | 0.180 |
Why?
| Microvessels | 2 | 2018 | 68 | 0.180 |
Why?
| Inpatients | 1 | 2024 | 380 | 0.180 |
Why?
| Prevalence | 6 | 2014 | 2252 | 0.170 |
Why?
| Sports | 2 | 2019 | 178 | 0.170 |
Why?
| Patient Dropouts | 1 | 2020 | 66 | 0.170 |
Why?
| Treatment Outcome | 11 | 2022 | 9105 | 0.170 |
Why?
| Carotid Arteries | 2 | 2013 | 180 | 0.170 |
Why?
| Coronary Vessels | 2 | 2014 | 230 | 0.170 |
Why?
| Brachial Artery | 3 | 2016 | 176 | 0.160 |
Why?
| Follow-Up Studies | 8 | 2019 | 4427 | 0.160 |
Why?
| Evidence-Based Medicine | 2 | 2014 | 675 | 0.160 |
Why?
| Administration, Intranasal | 2 | 2016 | 75 | 0.160 |
Why?
| Bacterial Vaccines | 1 | 1999 | 61 | 0.160 |
Why?
| Infant | 7 | 2019 | 7937 | 0.160 |
Why?
| Antihypertensive Agents | 3 | 2014 | 429 | 0.150 |
Why?
| Pneumococcal Infections | 1 | 1999 | 91 | 0.150 |
Why?
| Cardiotonic Agents | 1 | 2018 | 119 | 0.150 |
Why?
| Biomedical Technology | 1 | 2018 | 40 | 0.150 |
Why?
| Streptococcus pneumoniae | 1 | 1999 | 134 | 0.150 |
Why?
| Transplantation Conditioning | 1 | 2019 | 152 | 0.150 |
Why?
| Endocrinology | 1 | 2018 | 69 | 0.150 |
Why?
| Aged | 12 | 2023 | 19122 | 0.140 |
Why?
| Ohio | 5 | 2015 | 135 | 0.140 |
Why?
| Diabetic Cardiomyopathies | 2 | 2016 | 34 | 0.140 |
Why?
| Adolescent Nutritional Physiological Phenomena | 1 | 2017 | 25 | 0.140 |
Why?
| Sex Factors | 5 | 2016 | 1721 | 0.140 |
Why?
| Cross-Sectional Studies | 7 | 2017 | 4407 | 0.140 |
Why?
| Risk Assessment | 4 | 2014 | 2975 | 0.140 |
Why?
| Regression Analysis | 4 | 2014 | 947 | 0.140 |
Why?
| Proprotein Convertase 9 | 1 | 2017 | 61 | 0.140 |
Why?
| Immunization | 1 | 1999 | 402 | 0.140 |
Why?
| Aorta | 1 | 2018 | 390 | 0.130 |
Why?
| Surveys and Questionnaires | 7 | 2021 | 4635 | 0.130 |
Why?
| Inflammation | 2 | 2018 | 2485 | 0.130 |
Why?
| Colorado | 9 | 2017 | 4091 | 0.130 |
Why?
| Wyoming | 1 | 2015 | 17 | 0.130 |
Why?
| Perception | 1 | 2018 | 311 | 0.130 |
Why?
| Pediatric Obesity | 2 | 2019 | 489 | 0.130 |
Why?
| Coronary Disease | 3 | 2007 | 347 | 0.130 |
Why?
| Periodontal Diseases | 1 | 2015 | 57 | 0.130 |
Why?
| Delivery of Health Care | 1 | 2022 | 834 | 0.130 |
Why?
| Metformin | 1 | 2018 | 278 | 0.120 |
Why?
| Lipoproteins | 2 | 2022 | 160 | 0.120 |
Why?
| Hormones | 1 | 2015 | 133 | 0.120 |
Why?
| Videoconferencing | 1 | 2015 | 57 | 0.120 |
Why?
| Hospitalization | 1 | 2024 | 1754 | 0.120 |
Why?
| Consensus | 3 | 2023 | 534 | 0.120 |
Why?
| Sleep | 2 | 2022 | 632 | 0.120 |
Why?
| Self Care | 2 | 2014 | 350 | 0.120 |
Why?
| Patient Satisfaction | 1 | 2018 | 583 | 0.120 |
Why?
| Atherosclerosis | 3 | 2015 | 342 | 0.120 |
Why?
| Circadian Rhythm | 2 | 2015 | 355 | 0.120 |
Why?
| Vascular Calcification | 1 | 2016 | 107 | 0.120 |
Why?
| Pandemics | 1 | 2022 | 1325 | 0.110 |
Why?
| Creatinine | 2 | 2015 | 424 | 0.110 |
Why?
| Ketosis | 1 | 2014 | 12 | 0.110 |
Why?
| Dietary Fiber | 1 | 2014 | 40 | 0.110 |
Why?
| Parents | 4 | 2022 | 1191 | 0.110 |
Why?
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 525 | 0.110 |
Why?
| Goals | 1 | 2015 | 151 | 0.110 |
Why?
| Pediatrics | 2 | 2018 | 984 | 0.110 |
Why?
| Monitoring, Physiologic | 1 | 2015 | 248 | 0.110 |
Why?
| Prognosis | 6 | 2020 | 3344 | 0.110 |
Why?
| Registries | 3 | 2020 | 1760 | 0.110 |
Why?
| Bionics | 2 | 2022 | 11 | 0.110 |
Why?
| Longitudinal Studies | 6 | 2016 | 2382 | 0.110 |
Why?
| Obesity | 3 | 2020 | 2514 | 0.100 |
Why?
| Acetaminophen | 1 | 2015 | 238 | 0.100 |
Why?
| Femoral Artery | 1 | 2013 | 167 | 0.100 |
Why?
| Vitamin D Deficiency | 1 | 2013 | 158 | 0.100 |
Why?
| Kidney Function Tests | 1 | 2011 | 140 | 0.090 |
Why?
| Precision Medicine | 1 | 2014 | 339 | 0.090 |
Why?
| Infant, Newborn | 4 | 2019 | 5035 | 0.090 |
Why?
| Thyroidectomy | 1 | 2010 | 52 | 0.090 |
Why?
| Vitamin D | 1 | 2013 | 341 | 0.090 |
Why?
| United States | 8 | 2020 | 12211 | 0.090 |
Why?
| Injections, Subcutaneous | 2 | 2020 | 134 | 0.090 |
Why?
| Hypolipidemic Agents | 2 | 2008 | 87 | 0.090 |
Why?
| Outpatients | 3 | 2021 | 328 | 0.080 |
Why?
| Glycosuria | 1 | 2009 | 8 | 0.080 |
Why?
| Blood Flow Velocity | 2 | 2010 | 387 | 0.080 |
Why?
| Diabetes Mellitus | 3 | 2018 | 904 | 0.080 |
Why?
| Double-Blind Method | 3 | 2021 | 1663 | 0.080 |
Why?
| Combined Modality Therapy | 3 | 2017 | 1126 | 0.080 |
Why?
| Mobile Applications | 2 | 2020 | 140 | 0.070 |
Why?
| Life Style | 2 | 2008 | 430 | 0.070 |
Why?
| Clinical Trials as Topic | 1 | 2012 | 934 | 0.070 |
Why?
| Angiotensin II Type 2 Receptor Blockers | 1 | 2007 | 7 | 0.070 |
Why?
| Age Distribution | 2 | 2006 | 340 | 0.070 |
Why?
| Cold Temperature | 2 | 2019 | 128 | 0.070 |
Why?
| Health Promotion | 1 | 2014 | 686 | 0.070 |
Why?
| Disease Progression | 5 | 2018 | 2392 | 0.070 |
Why?
| Equipment Design | 2 | 2019 | 511 | 0.070 |
Why?
| Radionuclide Imaging | 1 | 2007 | 115 | 0.070 |
Why?
| Meals | 2 | 2019 | 102 | 0.070 |
Why?
| Catheter Ablation | 1 | 2010 | 291 | 0.070 |
Why?
| Time Factors | 3 | 2014 | 6125 | 0.070 |
Why?
| Smoking | 1 | 2014 | 1391 | 0.070 |
Why?
| Fetal Distress | 1 | 2006 | 12 | 0.070 |
Why?
| Renin-Angiotensin System | 1 | 2007 | 71 | 0.070 |
Why?
| Polymorphism, Genetic | 2 | 2007 | 612 | 0.070 |
Why?
| Apolipoproteins A | 1 | 2006 | 18 | 0.070 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2007 | 180 | 0.070 |
Why?
| Diagnosis, Differential | 1 | 2010 | 1355 | 0.070 |
Why?
| Pregnancy Complications, Cardiovascular | 1 | 2006 | 64 | 0.070 |
Why?
| Seasons | 2 | 2019 | 449 | 0.070 |
Why?
| Postprandial Period | 2 | 2018 | 87 | 0.070 |
Why?
| Hypertrophy | 2 | 2016 | 111 | 0.060 |
Why?
| Family Health | 1 | 2006 | 194 | 0.060 |
Why?
| Pregnancy in Diabetics | 1 | 2006 | 82 | 0.060 |
Why?
| Linear Models | 3 | 2014 | 770 | 0.060 |
Why?
| Infant, Newborn, Diseases | 1 | 2006 | 104 | 0.060 |
Why?
| Radiography | 1 | 2007 | 819 | 0.060 |
Why?
| Feasibility Studies | 2 | 2018 | 737 | 0.060 |
Why?
| Prospective Studies | 3 | 2022 | 6218 | 0.060 |
Why?
| Hair | 1 | 2004 | 65 | 0.060 |
Why?
| Sex Distribution | 1 | 2005 | 336 | 0.060 |
Why?
| Glucose Intolerance | 1 | 2005 | 138 | 0.060 |
Why?
| Cotinine | 1 | 2004 | 69 | 0.060 |
Why?
| Rats | 1 | 2012 | 4963 | 0.060 |
Why?
| Stroke | 1 | 2012 | 1019 | 0.060 |
Why?
| Hemodynamics | 2 | 2022 | 1014 | 0.060 |
Why?
| Incidence | 3 | 2014 | 2316 | 0.060 |
Why?
| Seizures | 1 | 2006 | 340 | 0.060 |
Why?
| Inflammation Mediators | 1 | 2006 | 476 | 0.050 |
Why?
| Glucose | 2 | 2021 | 897 | 0.050 |
Why?
| Predictive Value of Tests | 3 | 2015 | 1801 | 0.050 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2005 | 350 | 0.050 |
Why?
| Chitinase-3-Like Protein 1 | 1 | 2022 | 17 | 0.050 |
Why?
| Societies, Medical | 2 | 2018 | 677 | 0.050 |
Why?
| Reference Values | 2 | 2018 | 741 | 0.050 |
Why?
| Tobacco Smoke Pollution | 1 | 2004 | 217 | 0.050 |
Why?
| Insulin-Secreting Cells | 1 | 2005 | 317 | 0.050 |
Why?
| Motor Activity | 2 | 2018 | 642 | 0.050 |
Why?
| Behavior Therapy | 1 | 2023 | 226 | 0.050 |
Why?
| Environmental Exposure | 1 | 2004 | 377 | 0.050 |
Why?
| Sitosterols | 1 | 2020 | 1 | 0.050 |
Why?
| Logistic Models | 1 | 2005 | 1844 | 0.040 |
Why?
| Phytosterols | 1 | 2020 | 11 | 0.040 |
Why?
| Pancreas | 1 | 2022 | 277 | 0.040 |
Why?
| Intention to Treat Analysis | 1 | 2020 | 68 | 0.040 |
Why?
| Social Conditions | 1 | 2019 | 11 | 0.040 |
Why?
| India | 1 | 2020 | 134 | 0.040 |
Why?
| Retrospective Studies | 5 | 2014 | 12544 | 0.040 |
Why?
| Fear | 1 | 2022 | 291 | 0.040 |
Why?
| Autonomic Nervous System Diseases | 1 | 2019 | 27 | 0.040 |
Why?
| Factor Analysis, Statistical | 1 | 2020 | 257 | 0.040 |
Why?
| Personal Satisfaction | 1 | 2021 | 182 | 0.040 |
Why?
| Anthropometry | 1 | 2019 | 180 | 0.040 |
Why?
| Vaccines, Conjugate | 1 | 1999 | 60 | 0.040 |
Why?
| Smartphone | 1 | 2019 | 70 | 0.040 |
Why?
| Waist Circumference | 1 | 2018 | 122 | 0.040 |
Why?
| Sex Characteristics | 2 | 2017 | 635 | 0.040 |
Why?
| Drug Therapy, Combination | 1 | 2021 | 954 | 0.040 |
Why?
| International Cooperation | 1 | 2018 | 172 | 0.040 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2023 | 1215 | 0.040 |
Why?
| Interdisciplinary Communication | 1 | 2019 | 185 | 0.040 |
Why?
| Accelerometry | 1 | 2018 | 73 | 0.040 |
Why?
| Virginia | 1 | 2017 | 51 | 0.040 |
Why?
| Ambulatory Care Facilities | 1 | 2019 | 213 | 0.040 |
Why?
| Age of Onset | 1 | 2018 | 448 | 0.040 |
Why?
| Magnetic Resonance Angiography | 1 | 2018 | 221 | 0.030 |
Why?
| Child Nutritional Physiological Phenomena | 1 | 2017 | 97 | 0.030 |
Why?
| Magnetic Resonance Imaging | 1 | 2007 | 3053 | 0.030 |
Why?
| Vascular Capacitance | 1 | 2016 | 3 | 0.030 |
Why?
| Mass Spectrometry | 1 | 2019 | 633 | 0.030 |
Why?
| Family | 1 | 2020 | 590 | 0.030 |
Why?
| Food Preferences | 1 | 2017 | 108 | 0.030 |
Why?
| Powders | 1 | 2016 | 38 | 0.030 |
Why?
| Equipment Failure | 1 | 2016 | 107 | 0.030 |
Why?
| Nausea | 1 | 2016 | 104 | 0.030 |
Why?
| Injections, Intramuscular | 1 | 2016 | 118 | 0.030 |
Why?
| Drug Delivery Systems | 1 | 2018 | 296 | 0.030 |
Why?
| Ankle Brachial Index | 1 | 2015 | 30 | 0.030 |
Why?
| Child Behavior | 1 | 2017 | 220 | 0.030 |
Why?
| Early Diagnosis | 1 | 2016 | 217 | 0.030 |
Why?
| International Agencies | 1 | 2014 | 29 | 0.030 |
Why?
| Apolipoproteins | 1 | 2014 | 36 | 0.030 |
Why?
| Program Evaluation | 1 | 2019 | 824 | 0.030 |
Why?
| United States Food and Drug Administration | 1 | 2015 | 172 | 0.030 |
Why?
| Patient Care Team | 1 | 2019 | 516 | 0.030 |
Why?
| Hydrogen-Ion Concentration | 1 | 2015 | 512 | 0.030 |
Why?
| Societies, Scientific | 1 | 2014 | 47 | 0.030 |
Why?
| Activities of Daily Living | 1 | 2017 | 350 | 0.030 |
Why?
| Adolescent Medicine | 1 | 2014 | 33 | 0.030 |
Why?
| China | 1 | 2014 | 162 | 0.030 |
Why?
| Pressure | 1 | 2014 | 218 | 0.030 |
Why?
| Nutrition Policy | 1 | 2014 | 53 | 0.030 |
Why?
| Risk | 1 | 2016 | 815 | 0.030 |
Why?
| Primary Prevention | 1 | 2015 | 171 | 0.030 |
Why?
| Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 243 | 0.030 |
Why?
| Fibrinogen | 1 | 2014 | 154 | 0.030 |
Why?
| Feeding Behavior | 1 | 2018 | 572 | 0.030 |
Why?
| Up-Regulation | 1 | 2015 | 812 | 0.030 |
Why?
| Diabetic Retinopathy | 1 | 2014 | 149 | 0.030 |
Why?
| American Heart Association | 1 | 2014 | 264 | 0.030 |
Why?
| Dose-Response Relationship, Drug | 1 | 2016 | 1856 | 0.020 |
Why?
| Genotype | 2 | 2007 | 1775 | 0.020 |
Why?
| Quality Improvement | 1 | 2019 | 954 | 0.020 |
Why?
| Animals | 1 | 2012 | 31839 | 0.020 |
Why?
| Practice Patterns, Physicians' | 1 | 2018 | 1177 | 0.020 |
Why?
| Pulsatile Flow | 1 | 2010 | 54 | 0.020 |
Why?
| Elasticity | 1 | 2010 | 190 | 0.020 |
Why?
| Arm | 1 | 2010 | 104 | 0.020 |
Why?
| South Carolina | 1 | 2008 | 40 | 0.020 |
Why?
| Models, Biological | 1 | 2015 | 1630 | 0.020 |
Why?
| Lipoproteins, HDL | 1 | 2008 | 76 | 0.020 |
Why?
| Nutrition Therapy | 1 | 2008 | 31 | 0.020 |
Why?
| Leg | 1 | 2010 | 225 | 0.020 |
Why?
| Lipoproteins, LDL | 1 | 2008 | 128 | 0.020 |
Why?
| Angiotensins | 1 | 2007 | 10 | 0.020 |
Why?
| Receptor, Angiotensin, Type 1 | 1 | 2007 | 20 | 0.020 |
Why?
| Peptidyl-Dipeptidase A | 1 | 2007 | 53 | 0.020 |
Why?
| Pancreatic Function Tests | 1 | 2005 | 3 | 0.020 |
Why?
| Amino Acid Substitution | 1 | 2006 | 262 | 0.020 |
Why?
| Tomography, X-Ray Computed | 1 | 2014 | 2326 | 0.020 |
Why?
| C-Peptide | 1 | 2005 | 138 | 0.020 |
Why?
| Glucose Tolerance Test | 1 | 2005 | 343 | 0.010 |
Why?
| Population Surveillance | 1 | 2006 | 392 | 0.010 |
Why?
| Mother-Child Relations | 1 | 2004 | 111 | 0.010 |
Why?
| Endothelium, Vascular | 1 | 2008 | 848 | 0.010 |
Why?
| Oxidative Stress | 1 | 2006 | 1084 | 0.010 |
Why?
| DNA | 1 | 2006 | 1351 | 0.010 |
Why?
| Pregnancy | 1 | 2006 | 5527 | 0.010 |
Why?
|
|
Wadwa's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|